Abstract: This invention relates to 9-thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful for the treatment of skin diseases such as psoriasis, for the prevention of thrombus formation, in stimulating the production of growth hormone in intact animals, and as regulators of the immune response.
Type:
Grant
Filed:
November 22, 1976
Date of Patent:
April 18, 1978
Assignee:
Merck & Co., Inc.
Inventors:
Edward J. Cragoe, Jr., John B. Bicking, Robert L. Smith
Abstract: This invention relates to a colloid-forming composition useful in medical diagnosis. More particularly, it relates to an improved kit useful as a diagnostic aid comprising colloid-forming reagent solutions.It further relates to a kit useful in medical diagnosis which comprises in combination a lyophilized Stannous-phytate complex and a buffered calcium chloride solution.
Abstract: This invention relates to 9-thia-, 9-oxothia, and 9-dioxothia-11,12-seco-prostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful for the treatment of skin diseases such as psoriasis, for the prevention of thrombus formation, in stimulating the production of growth hormone in intact animals, and as regulators of the immune response.
Type:
Grant
Filed:
November 22, 1976
Date of Patent:
January 3, 1978
Assignee:
Merck & Co., Inc.
Inventors:
Edward J. Cragoe, Jr., John B. Bicking, Robert L. Smith
Abstract: This invention relates to 11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, for the treatment of hypertension, for the prevention of thrombus formation, in preventing gastric secretion, and as regulators of the immune response.
Type:
Grant
Filed:
March 22, 1976
Date of Patent:
January 3, 1978
Assignee:
Merck & Co., Inc.
Inventors:
Edward J. Cragoe, Jr., John B. Bicking, Robert L. Smith
Abstract: The new 4-aminomethyldibenzobicyclo[ 5.1.0] octane compounds of the present invention are prepared from the corresponding 4-halo compounds by reaction with a metal cyanide to produce the corresponding 4-cyano compound, which is reduced with an alkali metal aluminum hydride to produce the desired 4-aminomethyl compound. These new aminomethyldibenzobicyclo[ 5.1.0] octane compounds are converted to the corresponding secondary and tertiary amino derivatives.These new compounds are useful as antiarrhythmic agents and can be used to overcome cardiac irregularities.
Abstract: This invention relates to aryloxy-, alkoxy-, arylthio-, and alkylthio-11,12-seco-prostaglandins and to processes for their manufacture. These compounds have prostaglandin-like activity and are particularly useful in fertility control such as for estrus synchronization in animals and postcoital contraceptive agents in humans.
Abstract: This invention relates to 11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, for the treatment of hypertension, and for the prevention of thrombus formation.
Abstract: This invention relates to novel 8-aza-9-oxo-11-thia-, -11-oxothia-, and -11-dioxothia-prostanoic acid compounds, salts, and derivatives thereof and also to processes for the preparation of such compounds. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, for the treatment of certain autoimmune diseases, and in preventing thrombus formation.
Type:
Grant
Filed:
May 24, 1976
Date of Patent:
November 22, 1977
Assignee:
Merck & Co., Inc.
Inventors:
Robert L. Smith, Ta-Jyh Lee, Edward J. Cragoe, Jr.
Abstract: This invention relates to 11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, for the treatment of hypertension, and for the prevention of thrombus formation.
Abstract: This invention relates to 10-aza-11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators.
Abstract: The invention is concerned with novel 16-aryloxy-, 16-alkoxy-, 16-arylthio- and 16-alkylthio-8-aza-9-dioxothia-11,12-seco-prostaglandins and processes for their preparation. These novel compounds are useful as pharmaceuticals since they can be used in animals for estrus synchronization and treatment of infertility due to persistence of luteal function.
Abstract: This invention relates to 8-aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, for the prevention of thrombus formation, to induce growth hormone release, and as regulators of the immune response.
Abstract: This invention relates to novel 9-thia-, 9-oxothia-, and 9-dioxothia-11-oxo-12-azaprostanoic acid compounds, salts, and derivatives thereof and also to processes for the preparation of such compounds. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, as platelet aggregation inhibitors, and for the treatment of certain autoimmune diseases.
Type:
Grant
Filed:
May 24, 1976
Date of Patent:
May 10, 1977
Assignee:
Merck & Co., Inc.
Inventors:
Robert L. Smith, Ta-Jyh Lee, Edward J. Cragoe, Jr.
Abstract: This invention relates to aryloxy-, and alkoxy-, arylthio-, and alkylthio-11,12-seco-prostaglandins and to processes for their manufacture. These compounds have prostaglandin-like activity and are particularly useful in fertility control such as for estrus synchronization in animals and postcoital contraceptive agents in humans.
Abstract: This invention relates to 9-thia-, 9-oxothia, and 9-dioxothia-11,12-seco-prostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful for the treatment of skin diseases such as psoriasis, for the prevention of Thrombus formation, in stimulating the production of growth hormone in intact animals, and as regulators of the immune response.
Type:
Grant
Filed:
March 22, 1976
Date of Patent:
April 19, 1977
Assignee:
Merck & Co., Inc.
Inventors:
Edward J. Cragoe, Jr., John B. Bicking, Robert L. Smith
Abstract: The invention relates to a new and novel synthesis of prostaglandin E.sub.2, and it particularly relates to a novel process starting with relatively inexpensive starting materials. The invention further relates to a synthesis which is readily adaptable for large scale processing because of the high yields in the individual reaction steps.The invention further relates to novel compounds formed as intermediates in the synthesis of prostaglandin E.sub.2. The invention still further relates to synthetic analogs and known metabolites of prostaglandin E.sub.2 and prostaglandin E.sub.1, useful as standards in certain biological assays for determining prostaglandin-like activity.
Abstract: This invention relates to derivatives of dibenzocycloheptenes. In particular, the invention relates to dibenzocycloheptenes which are substituted at the 5-position with an aminomethyl group and to methods of preparing the same. The invention also relates to intermediates which are useful in the preparation of the above compounds and to methods for preparing the same.